Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaws (MRONJ)–formerly referred to as bisphosphonate-related osteonecrosis of the jaws …

Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaw (MRONJ) were set forth in the American Association of Oral and Maxillofacial …

Background Osteonecrosis of the jaw (ONJ) has been reported in patients receiving
bisphosphonates for metastatic bone disease. ONJ incidence, risk factors, and outcomes …

Bisphosphonates are used in the treatment of hypercalcemia of malignancy, skeletal
complications associated with metastastic bone disease, Paget's disease, and osteoporosis …

Objectives Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of
bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP …

Bisphosphonates are the most widely prescribed drugs for the treatment of osteoporosis,
and are also used in malignant bone metastases, multiple myeloma, and Paget's disease …

The use of bisphosphonate drugs has been popularised in the late 20th century for the
management of many conditions associated with abnormalities of bone turnover, particularly …

Objectives To compare success rates between the sub‐periosteal prepared (SPP) muco‐
periosteal flap and the epi‐periosteal prepared (EPP) mucosa flap and the feasibility of …

Osteoradionecrosis of the jaw remains the most problematic consequence of radiotherapy
for the management of head and neck cancer. Treatment is often complex and multimodal …

Bisphosphonates are inhibitors of osteoclastic bone resorption with therapeutic benefit in a
variety of bone disorders in both adults and children. While these agents have been …